My area of expertise is haematopathology with a focus on lymphomas, bone marrow pathology and molecular pathology. I have been in the field of haematopathology for over 25 years, and I have worked/trained across three continents (Europe, Asia and North America). At the Hammersmith Hospital / Imperial College, I lead diagnostics, translational research and training in haematopathology. My referral practice caters to haematopathologists across the UK, and to many other haematopathologists outside of UK. I am the current Chair of the British Lymphoma Pathology Group (BLPG). Through my activities in BLPG and Royal College of Pathologists, I play a critical role in improving standards of training and practice of haematopathology in the UK. I have over 240 publications, majority of which are in the field of haematopathology. In haematopathology research, my collaborations extend across the UK, and I also collaborate with investigators and institutions in Europe, United States, Asia and Africa. I am a firm believer in global medicine and science and in fostering international collaboration to promote translational research and training in haematopathology and in other branches of medicine.
At Imperial, I have been responsible for building the Specialist Integrated Haematological Malignancy Diagnostic Service (SIHMDS) at Imperial. This is a centralised service for a large number of hospitals in and around London. I have also led the development of a supra-regional / national lymphoma referral service at the Hammersmith Hospital and supports diagnosis of challenging cases from across the country. I also lead on molecular diagnostic services and on genomics at Imperial.
I have been responsible for leading the NIHR’s Clinical Academic Training programme in Histopathology at the Hammersmith Hospital / Imperial since its inception in 2006. Through this, I have been mentoring and training the clinical academics of the future. I have other major commitments in education – clinical training in histopathology & haematology; postgraduate education (PhD, MRes & MSc) and undergraduate education. I support the specialised training of haematopathologists from all over UK and rest of the world. I contribute to education in haematopathology by lecturing in many local, regional, national and international meetings.
I also lead activities of cellular and molecular pathology in the Imperial Biomedical Research Centre. My primary research interest and those that I drive, pertain to translational research. I also support other investigators undertaking translational and basic research. Most of the research that I drive is focussed on lymphoid malignancies. I also dwell to a lesser extent on plasma cell, myeloid and other haematological malignancies. My translational research interests can be summarised under:
- Genomics of B cell lymphomas
- Genomics of T cell lymphomas
- Biology of Immune deficiency lymphoid proliferations including proliferations in post-transplant and HIV settings.
- Biology of Hodgkin lymphoma
- Role of micro-environment in maintenance and evolution of malignant lymphoid populations
- Biology of oncogenic viruses in lymphomagenesis and patient outcomes
- Early steps and lesions in lymphomagenesis and pathways of evolution
- Developing diagnostic algorithms using immunohistochemistry and other ancillary tools for lymphomas.
- Identification of unique subtypes of lymphomas and lymphoid proliferations leading to refinements in classification of disease
- Establishing new antibodies in the diagnosis of different lymphoma categories.
- Biomarker discovery – for stratifying haematological malignancies
- Correlation of immunohistochemistry and flow cytometry in diagnostic haemato-oncology
- Refining criteria for diagnosis on bone marrow trephine biopsies
- Disease evolution following stem cell transplantation
- Epidemiology and molecular epidemiology of lymphomas
- Myeloma research
I have been in various leadership positions at all levels – local, regional, national and international.
et al., 2020, Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date., British Journal of Haematology, Vol:189, ISSN:0007-1048, Pages:1062-1063
et al., 2020, Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients, Leukemia, ISSN:0887-6924
Medani H, Elshiekh M, Naresh K, 2020, Accurate Mitotic Counts in Mantle Cell Lymphoma Using Phosphohistone H3 (PHH3) Immunohistochemistry, 109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), NATURE PUBLISHING GROUP, Pages:1346-1347, ISSN:0893-3952
et al., 2020, Bone Marrow Trephine Biopsy in Patients of Primary Immune Thrombocytopenia on Treatment with Thrombopoietin Receptor Agonists, 109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), NATURE PUBLISHING GROUP, Pages:1348-1348, ISSN:0023-6837
et al., 2020, Bone Marrow Trephine Biopsy in Patients of Primary Immune Thrombocytopenia on Treatment with Thrombopoietin Receptor Agonists, 109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), NATURE PUBLISHING GROUP, Pages:1348-1348, ISSN:0893-3952